Your session is about to expire
← Back to Search
Study Summary
This trial is testing a new drug to see if it is safe and effective in treating patients with a primary glomerular disease who have persistent proteinuria.
- Proteinuria
- Glomerulonephritis
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any current opportunities for enrolling in this investigation?
"Indeed, the clinical trials platform indicates that this research is still recruiting participants. The project was created on December 24th 2021 and its requirements were last adjusted on March 22nd 2022. To date, 100 subjects are yet to be enrolled at 18 different sites."
What is the geographic scope of this clinical experiment?
"This trial is being conducted at Amicis Research Center in Northridge, CA; University of Pennsylvania in Philadelphia, PA; The Johns Hopkins Hospital in Baltimore, MD and 18 other medical centres."
How many individuals have enrolled in this study thus far?
"Affirmative. Clinical trials data on clinicaltrials.gov reveals that this investigation is actively recruiting participants, having first been posted to the site on December 24th 2021 and last updated on March 22nd 2022. A total of 100 patients need to be enrolled across 18 different medical sites."
Has the federal agency sanctioned ANG-3070 for medical use?
"The safety of ANG-3070 is estimated to be a 2 on the scale, as this Phase 2 trial has only collected limited data regarding its efficacy. However, there is evidence to suggest it can be safely administered."
Share this study with friends
Copy Link
Messenger